OS Therapies Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OSTX NYSE American 2836 ostherapies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OS Therapies Incorporated

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program - Jul 8th, 2026 7:00 am
OS Therapies Third Quarter 2026 Corporate Outlook - Jul 6th, 2026 7:00 am
OS Therapies Appoints Dr. Craig Eagle to Board of Directors - Jul 2nd, 2026 5:30 am
OS Therapies Provides U.S. Regulatory Update - Jun 30th, 2026 5:40 am
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma - Jun 26th, 2026 5:40 am
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma - Jun 8th, 2026 4:00 am
OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma - Jun 2nd, 2026 4:25 am
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma - Jun 2nd, 2026 4:00 am
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World - May 29th, 2026 5:20 am
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences - May 26th, 2026 5:40 am
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update - May 18th, 2026 4:30 am
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 - May 15th, 2026 2:05 pm
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor - May 14th, 2026 5:30 am
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) - May 12th, 2026 12:35 pm
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma - Apr 30th, 2026 4:00 am
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes - Apr 16th, 2026 5:20 am
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor - Apr 13th, 2026 4:00 am
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor - Apr 8th, 2026 9:38 am
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors - Apr 2nd, 2026 3:15 pm